Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function

• Үндсэн зохиолчид: Masatoshi Abe (Зохиогч), Hajime Iizuka (Зохиогч), Ikue Nemoto‐Hasebe (Зохиогч), Osamu Nemoto (Зохиогч), Hiroyuki Toyama (Зохиогч), Katsuyo Ohashi‐Doi (Зохиогч), Kenji Kabashima (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Objectives Delgocitinib is a small‐molecule JAK inhibitor that has recently been approved in Japan as the world's first topical JAK/STAT pathway inhibitor for the treatment of atopic dermatitis (AD). In this study, the effects of delgocitinib 0.5% ointment treatment on skin rash severi...